Authors

3 Common eCOA Implementation Challenges and How to Solve Them

Overcoming hurdles with licensing complexities, post-production changes, and IRB submissions can help in reducing timelines and increasing collaboration.

Four Strategic Considerations to Choose an EDC

Companies share their experience in future-proofing clinical data technology.

Addressing Population Gaps in Therapy Adoption: Using Real-World Data to Bridge the Clinical Trial Divide

How clinical operations teams can close the gap between controlled trial results and real-world adoption by generating evidence in broader, more representative patient populations.

The Future is Now: Four Ways AI and Other Tech Advances are Enhancing Clinical Trials

Emerging applications of AI/ML, automation, and digitization are helping sponsors cut clinical trial start-up times to as little as four weeks, reduce data errors, and enhance patient engagement—demonstrating how tech-enabled processes are reshaping trial efficiency and experience across the study lifecycle.

Preparing to Achieve with Joint Clinical Assessments

Strategies for sponsors in navigating the European Union's new health technology assessment regulation.

In an Uncertain Policy Environment, Pharma Needs Timely Real-World Data More Than Ever

In an era of constant policy change, timely real-world data is emerging as pharma’s most critical tool to track patient access, anticipate shifts in treatment utilization, and improve outcomes in real time.

Modernizing Patient-Reported Outcomes: Bridging the Gap Between Legacy Measures and Contemporary Healthcare

Strategies for ensuring that innovation with PROs remains parallel with advancements in disease detection and progression.

Accelerate Inclusive Enrollment and Delivery with Lightship

David MacMurchy, Chief Executive Officer at Lightship, offers some insights into the company's mission toward improving equity and diversity in clinical trials.

Enhancing Empowerment in Patient-Focused Research

How the inclusion of measures centered on net treatment benefit can drive an effective multifaceted approach.

Transforming Healthcare Data

We are amidst a data revolution in healthcare and the life sciences. With advances in DNA sequencing, multiomics, wearables, imaging, and clinical data capture, there is more data — and there are more data modalities — to draw from for biomedical research than ever before. However, the quantity, variance and speed of data generation outpaces researchers’ ability to effectively utilize it to reveal medical breakthroughs for those in need. The ability to analyze health data is critical in developing a precision health approach. By leveraging diverse data sources, researchers can determine the most effective actions for individuals and communities. However, current barriers to data access and collaboration hinder progress. To accelerate the pace of discovery, a solution is needed to close the gap between research and health care. This paper describes how Verily Workbench provides solutions for healthcare professionals and researchers to easily access and collaborate on data within an integrated analysis and governance framework. Workbench provides a community of researchers with the platform, data, and tools to solve the most pressing scientific challenge

The Latest Advancements in Single Sign-On Technology

How today’s SSO reduces site burden and spearheads clinical system interoperability.

Beyond the Comment Section: Rebuilding Trust in Vaccines Through Conversation

Why discussions with patients should go deeper than data-centered dialogues—and emphasize trust, personal connections, and community engagement to foster informed choices in public health.

Rewiring Clinical Research: AI-Augmented Data, Processes, and People

AI as an accelerator for data-centric, process-centric, and human-centric clinical research.

Navigating the Intersection of Accessibility and Measurement Integrity in eCOA

Clinical research evolves to prioritize patient-centered outcomes, integrating accessibility standards in electronic data capture for inclusive clinical trials.

Digital Measures of Health: What’s in it for Patients?

Exploring the different stages in the development of a digital measure, and the activities and steps key to achieving meaningful impact for patients.

Answering the Sustainability Call: Digital Health Technologies and eCOA

Sustainability should be central to clinical trial design and considerate of how digital tools such as electronic clinical outcomes assessments can help achieve this.

From Automation to Self-Optimization: The Next Leap in Clinical Trial Delivery

Why future-ready pharma companies must embrace AI-driven, real-time decision-making.

Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit

In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.

Clinical Trial Monitoring: Should Randomization Be Included?

While randomization is required by regulatory bodies, it is up to the sponsor on how to conduct it.

Drug Repurposing Through AI-Driven In-Silico Clinical Trials

AI-driven discovery, EHR-based real-world evidence, and synthetic patient modeling are rapidly reshaping drug repurposing, reducing development timelines, expanding therapeutic applications, and accelerating regulatory acceptance of computational approaches.

Clinical Strategies to Optimize Software as a Medical Device to Treat Mental Health

With close collaboration between sponsors, CROs, and regulators, this emerging technology has the potential to greatly improve the lives of patients.

Answering the Sustainability Call: Digital Health Technologies and eCOA

Sustainability should be central to clinical trial design and considerate of how digital tools such as electronic clinical outcomes assessments can help achieve this.

Optimizing Clinical Trial Efficiency: The Power of Simplicity for First-in-Human Studies

How industry can increase the speed of these trials while continuing to meet patient needs.

Investigative Site Investment, Preparedness, and Experience with Digital Solutions

A new global Tufts CSDD survey of 387 investigative site professionals reveals broad experience with digital and decentralized trial tools, growing site-driven technology investments, and strong support for remote data collection—while highlighting persistent burdens tied to fragmented systems, training demands, and financial strain.

Accelerating Breakthroughs with Synthetic Clinical Trial Data

The emergence of AI-powered simulants in improving study efficiency.

Future Proofing Your Outsourcing Strategy: How to Stay Agile in a Fast-Moving Clinical Trial Ecosystem

A blend of FSO and FSP models in the landscape of artificial intelligence can ensure CROs stay up to date with the unique demands of industry.

Utilizing Tech Tools to Accelerate Drug Development

In a decentralized, digitally enabled clinical trial environment, conventional approaches to data analysis are evolving as sponsors utilize technological tools in new ways to ensure compliance with global standards, mitigate risk, and bring life-changing therapies to patients faster.

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

Reprioritizing DNA Damage Response: Leveraging Lessons Learned to Develop Next-Generation Inhibitors

Advancements in this field have the potential to transform cancer care and improve quality of life for patients.